Type of Deal: Rights issue subscription (100% ownership maintained)
Stake/Capacity: 10,00,000 equity shares acquired, maintaining Curexis as wholly-owned subsidiary
Deal Value: ₹2,00,00,000.00 (Two Crore Rupees)
Funding Source: Cash consideration
Financial Impact: Investment of ₹2 crore to support working capital requirements and expansion of SKIA retail pharmacy stores
Strategic Rationale: Strategic investment for expansion of SKIA stores and to mitigate the working capital requirements of Curexis. The investment supports the retail pharmacy business offering Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products.
Approval Status: Completed transaction
Reference Regulation: SEBI Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Additional Details:
Curexis was incorporated on February 25, 2025
Business: Drug manufacturing, development, and marketing company running retail pharmacy stores under brand "SKIA"
Financial performance: FY 2025-26 turnover ₹1.18 Lakhs, paid-up share capital ₹1 Lakh prior to rights issue
Transaction is not a related party transaction and executed at arm's length
No governmental or regulatory approvals required for the acquisition
Price per share: ₹20.00 (including premium of ₹10.00 per equity share)
